Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

31.6%

6 terminated/withdrawn out of 19 trials

Success Rate

68.4%

-18.1% vs industry average

Late-Stage Pipeline

21%

4 trials in Phase 3/4

Results Transparency

77%

10 of 13 completed trials have results

Key Signals

10 with results6 terminated

Enrollment Performance

Analytics

Phase 1

8(42.1%)

Phase 2

7(36.8%)

Phase 3

4(21.1%)

19Total

Phase 1(8)

Phase 2(7)

Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT04173494Phase 3Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Role: lead

NCT02101021Phase 3Terminated

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Role: lead

NCT02226965Phase 2Completed

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Role: lead

NCT02378038Phase 2Terminated

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Role: lead

NCT02797977Phase 1Completed

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Role: lead

NCT01733238Phase 2Completed

Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Role: lead

NCT02797964Phase 1Completed

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Role: lead

NCT02515630Phase 2Completed

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Role: lead

NCT02124746Phase 2Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Role: lead

NCT02101268Phase 3Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Role: lead

NCT01969838Phase 3Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Role: lead

NCT01191775Phase 1Completed

A Study of PNT2258 in Patients With Advanced Solid Tumors

Role: lead

NCT01998828Phase 2Terminated

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Role: lead

NCT01236638Phase 2Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Role: lead

NCT01423058Phase 1Completed

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Role: lead

NCT00935987Phase 1Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Role: lead

NCT02206763Phase 1Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Role: lead

NCT02258607Phase 1Terminated

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Role: lead

NCT02244489Phase 1Terminated

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Role: lead

All 19 trials loaded